Efficacy of myo‐inositol and d‐chiro‐inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open‐label study
Abstract
OBJECTIVE: To compare the effect of myo-inositol and d-chiro-inositol in combination (MI + DCI) with combined hormonal contraceptive (CHC) on menstrual cycle regulation in young Indian women with polycystic ovary syndrome (PCOS). METHODS: Seventy young women with PCOS aged 15-24 years with delayed cycles were randomized into two groups and were treated for 6 months with MI + DCI (550 + 150 mg, 3.6:1 ratio) twice a day and CHC (ethinyl estradiol 20 µg + drospirenone 3 mg) once a day. RESULTS: Spontaneous menses resumed in 28 (84.85%) young women on MI + DCI, compared with withdrawal bleeding in 34 (100%) on CHC. The mean cycle length reduced with both MI + DCI (124.54 ± 8.08 to 57.75 ± 3.00 days, P < 0.001) and CHC (105.88 ± 7.96 to 30.53 ± 2.95 days, P < 0.001). Regular menstrual cycles were established in 9 (27.27%) young women with MI + DCI (P = 0.001) and 30 (88.23%) with CHC (P < 0.001). Three months after stopping the treatment, 24 young women (85.71%) on MI + DCI and 25 (73.53%) on CHC continued to have spontaneous cycles. Anti-Müllerian hormone decreased with both the drugs (P = 0.001), whereas luteinizing hormone (P = 0.001) and testosterone (P = 0.04) decreased with CHC and homeostatic model assessment of insulin resistance (P < 0.001) with MI + DCI. CONCLUSION: Myo-inositol and d-chiro-inositol in combination (3.6:1 ratio) are effective in regularizing menstrual cycles and improving insulin resistance. TRIAL REGISTRATION: Clinical Trials Registry of India (CTRI/2018/03/012643). http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=20969&EncHid=&userName=myo-inositol.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
One included trial evaluated MI + DCI compared to a combined hormonal contraceptive.
“One trial evaluated MI + DCI compared to a combined hormonal contraceptive (CHC) (36).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [36]
One included study used a combined hormonal contraceptive, 20 μg ethinyl estradiol and 3 mg drospirenone, as a comparator.
“One study used a CHC, 20 µg ethinyl estradiol and 3 mg drospirenone, as a comparator (36).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [36]
In one trial of 70 women, after 6 months of MI + DCI compared to CHC, there was no significant difference in weight, BMI, WHR, HOMA-IR, fasting insulin, fasting blood glucose, or testosterone; at 3 months after stopping treatment, HOMA-IR and fasting insulin improved in the MI + DCI group; menstrual cycle length was shorter in the CHC group.
“One trial (n = 70) (36) assessed outcomes after 6 months of treatment and again 3 months after stopping treatment with MI + DCI compared to CHC. Results suggested no significant difference in weight, BMI, WHR, HOMA-IR, fasting insulin, fasting blood glucose, or testosterone after 6 months of treatment. There was improvement in HOMA-IR and fasting insulin level in the MI + DCI group when assessed 3”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [36]
Cites
1 retracted
Laganà, A. S., Barbaro, L., & Pizzo, A. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3552-6 · Cited by 71 · see citing works
RetractedDiamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · see citing works
Munro, M. G., Critchley, H., & Fraser, I. S. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12666 · Cited by 1,093 · see citing works
Ding, T., Hardiman, P. J., Petersen, I., Wang, F.-F., Qu, F., & Baio, G. (2017) · Oncotarget · doi:10.18632/oncotarget.19180 · Cited by 336 · see citing works
Lass, N., Kleber, M., Winkel, K., Wunsch, R., & Reinehr, T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1609 · Cited by 160 · see citing works
The diagnosis and treatment of PCOS in adolescents: an update
Witchel, S. F., Burghard, A. C., Tao, R., & Oberfield, S. E. (2019) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000778 · Cited by 128 · see citing works
Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women
Raffone, E., Rizzo, P., & Benedetto, V. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903366996 · Cited by 100 · see citing works
Tehrani, F. R., Amiri, M., Behboudi‐Gandevani, S., Yarandi, R. B., & Carmina, E. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1650337 · Cited by 93 · see citing works
Metformin or oral contraceptives for adolescents with polycystic ovarian syndrome: a meta-analysis
Al Khalifah, R. A., Florez, I. D., Dennis, B., Thabane, L., & Bassilious, E. (2016) · PEDIATRICS · doi:10.1542/peds.2015-4089 · Cited by 91 · see citing works
Bevilacqua, A., Carlomagno, G., Gerli, S., Oliva, M. M., Devroey, P., Lanzone, A., Soulage, C. O., Facchinetti, F., Renzo, G. C. D., Bizzarri, M., et al. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1006616 · Cited by 83 · see citing works
Wu, C., Grandi, S. M., Filion, K. B., Abenhaim, H., Joseph, L., & Eisenberg, M. J. (2013) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12210 · Cited by 73 · see citing works
Monastra, G., Unfer, V., Harrath, A. H., & Bizzarri, M. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1247797 · Cited by 71 · see citing works
Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis
Zeng, L., & Yang, K. (2018) · Endocrine · doi:10.1007/s12020-017-1442-y · Cited by 59 · see citing works
Inositols’ Importance in the Improvement of the Endocrine–Metabolic Profile in PCOS
Wojciechowska, A., Osowski, A., Jóźwik, M., Górecki, R. J., Rynkiewicz, A., & Wojtkiewicz, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225787 · Cited by 59 · see citing works
Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary
Roseff, S., & Montenegro, M. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6461254 · Cited by 52 · see citing works
Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols
Sortino, M. A., Salomone, S., Carruba, M. O., & Drago, F. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00341 · Cited by 48 · see citing works
Rosenfield, R. L., Ehrmann, D. A., & Littlejohn, E. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4290 · Cited by 42 · see citing works
Manzoor, S., Ganie, M. A., Amin, S., Shah, Z. A., Bhat, I. A., Yousuf, S. D., Jeelani, H., Kawa, I. A., Fatima, Q., & Rashid, F. (2019) · Scientific Reports · doi:10.1038/s41598-019-46644-4 · Cited by 40 · see citing works
Mendoza, N., Diaz-Ropero, M. P., Aragon, M., Maldonado, V., Llaneza, P., Lorente, J., Mendoza-Tesarik, R., Maldonado-Lobon, J., Olivares, M., & Fonolla, J. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1576620 · Cited by 36 · see citing works
Panidis, D., Τζιόμαλος, Κ., Papadakis, E. P., Chatzis, P., Kandaraki, E., Tsourdi, E. A., Μacut, D., Bjekić-Macut, J., Marthopoulos, A., & Katsikis, I. (2015) · HORMONES · doi:10.14310/horm.2002.1593 · Cited by 32 · see citing works
Myo-inositol vs. D-chiro inositol in PCOS treatment.
Formuso, C., Stracquadanio, M., & Ciotta, L. (2015) · PubMed · Cited by 22 · see citing works
Myoinositol Improves Embryo Development in PCOS Patients Undergoing ICSI
Wdowiak, A. (2016) · International Journal of Endocrinology · doi:10.1155/2016/6273298 · Cited by 16 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad762 · Cited by 70 · see citing works
“One trial (n = 70) (36) assessed outcomes after 6 months of treatment and again 3 months after stopping treatment with MI + DCI compared to CHC. Results suggested no significant difference in weight, BMI, WHR, HOMA-IR, fasting insulin, fasting blood glucose, or testosterone after 6 months of treatment.”
BackgroundInfluential
- Authors
- Kachhawa, G., Senthil Kumar, K. V., Kulshrestha, V., Khadgawat, R., Mahey, R., & Bhatla, N.
- Affiliations
- All India Institute of Medical Sciences (IN)
- Department of Obstetrics and Gynaecology All India Institute of Medical Sciences New Delhi India
- Corresponding author
- Kachhawa, Garima
- Venue
- International Journal of Gynecology & Obstetrics
- Publisher
- Wiley
- Published
- 2021-11-10
- Volume
- 158
- Issue
- 2
- Pages
- 278-284
- ISSN
- 0020-6695 (ISSN-L)
- 0020-7292
- 1879-3479
- OpenAlex
- W3202292672
- Cited by
- 18
- References
- 23
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 2 · 2023: 4 · 2022: 2
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Gynecology & Obstetrics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Biology and Fertility
- Keywords
- polycystic ovary syndrome, myo-inositol, D-chiro-inositol, menstrual cycle regulation, insulin resistance, drospirenone, ethinyl estradiol, anti-Müllerian hormone, luteinizing hormone, testosterone, young women, anovulation, withdrawal bleeding, HOMA
- MeSH terms
- Female, Humans, Inositol, Insulin Resistance, Luteinizing Hormone, Menstrual Cycle, Polycystic Ovary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
